The American Society of Clinical Oncology (ASCO) is the largest cancer related conference in the world.
ASCO is held the first week in June each year in Chicago. I covered ASCO last year for The Myeloma Beacon. This international event is HUGE!
If you have followed my blog for a while, you will be familiar with the hectic news cycle which proceeds large conferences like this one. Pharmaceutical companies begin to release “teaser” type news about clinical trial results they will be presenting two or three weeks prior to “kick-off.”
Thus far, there had only been a trickle of pre-ASCO related news–that is until yesterday. I counted seven different multiple myeloma related press releases in my in-box Friday. You can read about several of the most important at MyelomaNews.com.
But I wanted to share this Bristol-Myers Squibb/Abbott Labs news with you here now.
Bristol-Myers is one of the largest of the large international drug companies. Not your typically smaller, one or two compound drug company that specializes in multiple myeloma, Bristol-Myers announced yesterday that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7.
Wow! 95 already approved compounds. To put this in perspective, Celgene (Thalomid and Revlimid) and Millennium (Velcade) are only currently testing a half dozen or so compounds each.
Bristol-Myers big news this time around features several new melanoma related drugs, the best known to be a new, “wonder drug” for metastatic melanoma called YERVOY. That’s the drug you will see featured on morning television shows like Good Morning America and The Today Show in a few weeks.
But burried at the end of the official Bristol-Myers Squibb, pre-ASCO release, I found this:
Bristol-Myers Squibb and its partner, Abbott, will present updated Phase 1 and 2 results on elotuzumab, which is under development for the treatment of multiple myeloma. Elotuzumab is an investigational humanized monoclonal antibody specifically targeted against CS1, a cell-surface glycoprotein that is highly and uniformly expressed on multiple myeloma cells. On Sunday, June 5, updated results evaluating the safety and efficacy of elotuzumab plus lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma will be presented during an oral session. A Phase 3 clinical trial for elotuzumab in relapsed multiple myeloma was recently initiated and is now actively recruiting patients.
Many multiple myeloma experts expect the study results about elotuzumab to be impressive. More about elotuzmab–along with several other new, experimental anti-myeloma drugs–tomorrow.
Feel good and keep smiling! Pat